Current treatment at multiple myeloma
- Author:
- No author available
- Journal Title:
- Journal of Leukemia & Lymphoma
- Issue:
- 11
- DOI:
- 10.3760/cma.j.issn.1009-9921.2011.11.001
- Key Word:
- 多发性骨髓瘤;治疗;Multiple myeloma;Therapy
Abstract： The breakthrough progress has been made in the treatment of multiple myeloma.Since 1990 s,autologous stem-cell transplantation (ASCT) has resulted in high response rate of MM,and the median overall survival was 5 years.The recent introduction of the novel agents including thalidomide,bortezomib,and lenalidomide further increase the response rate of MM.It is reported that the median overall survival was increased by 50 ％.The latest estimates of the median overall survival was about 10 years in under 65 years old patients,and 5-6 years in the elderly patients.The novel agents under investigation will further prolong the overall survival rate and progression free survival in the near future.
- [1]陈世伦,邱录贵,江滨,等.硼替佐米联合沙利度胺在新诊断多发性骨髓瘤中的应用[J].2011,(4).
- [2]Kumar SK,Rajkumar SV,Dispenzieri A,etc.Improved survival in multiple myeloma and the impact of novel therapies.[J].2008,111(5).
- [3]Zabelina T,Brand R,Sayer HG,etc.Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.[J].2004,10(10).
- [4]Kyle RA,Rajkumar SV.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.[J].2009,23(1).
- [5]Lee C.-K..DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma[J].2003.
- [6]Roberts AW,Bradstock KF,Spencer A,etc.Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.[J].2009,27(11).
- [7]Tricot G,Anaissie E,Crowley J,etc.Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.[J].2008,140(6).
- [8]Morie A. Gertz,Martha Q. Lacy,Suzanne R. Hayman.Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma[J].2009,27(30).